NIH, FDA to tighten, review consulting rules as Congressional inquiry continues.
In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.
HHS lawyer tells of pressure to allow former NCI Director Richard Klausner to receive $40,000 prize.
Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.
In Brief: ASCO awards career development grants.
Funding Opportunities listed.
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.”